DESTINY-Breast06: determining HER2-(ultra)low status in HR+ mBC

DESTINY-Breast04: T-DXd for patients with HER2-low mBCПодробнее

Efficacy of trastuzumab deruxtecan in HER2-low metastatic breast cancerПодробнее

Remaining questions on the management of HER2-low breast cancerПодробнее

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecanПодробнее

DESTINY-Breast15: T-DXd in patients with HR+HR- and HER2-low or HER2 IHC 0 metastatic breast cancerПодробнее

DESTINY-Breast04: practice-changing results for HER2-low breast cancerПодробнее

Highlights in HER2-low breast cancer at SABCS 2022Подробнее

Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast CancerПодробнее

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysisПодробнее

The exciting new field of HER2-low breast cancerПодробнее

Investigating the influence of HER2 low status in LBCПодробнее

HER2+ mBC: Study Design and Results of DESTINY-Breast01Подробнее

HER2-low expression in breast cancerПодробнее

HER2-Low Breast Cancer: DESTINY or Good Science?Подробнее

Trastuzumab deruxtecan shows benefit in patients with HER2 + mBCПодробнее

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer ptsПодробнее

Unfold HER2 spectrum from HER2 + to HER2 low mBC between now, past and futureПодробнее

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patientsПодробнее